Get the Stockscreener App
3.50
3.55%
0.12
After Hours:
3.46
-0.04
-1.14%
Rezolute Inc stock is traded at $3.50, with a volume of 1.87M.
It is up +3.55% in the last 24 hours and up +31.09% over the past month.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
See More
Previous Close:
$3.38
Open:
$3.36
24h Volume:
1.87M
Relative Volume:
0.29
Market Cap:
$324.55M
Revenue:
-
Net Income/Loss:
$-69.31M
P/E Ratio:
-2.7559
EPS:
-1.27
Net Cash Flow:
$-62.80M
1W Performance:
+21.11%
1M Performance:
+31.09%
6M Performance:
-44.44%
1Y Performance:
-23.08%
1-Day Range:
$3.265
$3.59
1-Week Range:
$2.8501
$3.65
52-Week Range:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Name
Rezolute Inc
Sector
Industry
Phone
650-206-4507
Address
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
3.50 | 313.42M | 0 | -69.31M | -62.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-11-25 | Downgrade | Craig Hallum | Buy → Hold |
| Dec-11-25 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Aug-27-24 | Initiated | Guggenheim | Buy |
| Jul-17-24 | Initiated | BTIG Research | Buy |
| Jun-04-24 | Initiated | Craig Hallum | Buy |
| Apr-09-24 | Initiated | Maxim Group | Buy |
| Aug-02-22 | Resumed | Canaccord Genuity | Buy |
| Jun-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-21 | Initiated | ROTH Capital | Buy |
| May-27-21 | Initiated | Oppenheimer | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
View All
Rezolute Inc Stock (RZLT) Latest News
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - marketscreener.com
Analysis Recap: Will Rezolute Inc benefit from rate cutsJuly 2025 Volume & Low Volatility Stock Recommendations - baoquankhu1.vn
Faruqi & Faruqi Encourages Rezolute Investors to Discuss Legal Options - Intellectia AI
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - PR Newswire
RZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc.RZLT - PR Newswire
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - GlobeNewswire Inc.
Trading Recap: Is Rezolute Inc a top pick in the sectorPortfolio Gains Summary & Safe Swing Trade Setups - baoquankhu1.vn
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - The Malaysian Reserve
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - TMX Newsfile
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating - Sahm
FMR LLC Significantly Reduces Holdings in Rezolute Inc. - GuruFocus
Entry Recap: Is Rezolute Inc a top pick in the sectorMarket Activity Summary & Precise Swing Trade Alerts - baoquankhu1.vn
RZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - Chartmill
RZLT ALERT: Levi & Korsinsky Investigates Rezolute, Inc. for Possible Securities Fraud Violations - marketscreener.com
RZLT Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - marketscreener.com
Rezolute Downgrade Brings Investor Caution Amid Study Challenges - StocksToTrade
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - MarketScreener
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - TMX Newsfile
Is Rezolute Inc. stock positioned well for digital economyJuly 2025 Big Picture & Daily Volume Surge Signals - ulpravda.ru
Rezolute Updates sunRIZE Phase 3 Trial and FDA Plans - TipRanks
Did You Suffer Losses in Rezolute, Inc. (RZLT)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Does Rezolute Inc. stock trade at a discount to peersAnalyst Upgrade & Long-Term Safe Return Strategies - ulpravda.ru
Will Rezolute Inc. (6HV1) stock test record highs in 2025Market Activity Report & Fast Entry Momentum Alerts - ulpravda.ru
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - Bluefield Daily Telegraph
Rezolute (RZLT): Wedbush Analyst Raises Price Target to $2.00 | - GuruFocus
Why analysts upgrade Rezolute Inc. stockJuly 2025 Macro Moves & Free Fast Entry Momentum Trade Alerts - ulpravda.ru
Rezolute (NASDAQ:RZLT) Given Buy Rating at BTIG Research - MarketBeat
Jefferies reiterates Buy rating on Rezolute stock, maintains $4 target By Investing.com - Investing.com Canada
Wedbush Doubles Price Target on Rezolute to $2 From $1, Keeps Neutral Rating - marketscreener.com
BTIG Reiterates Buy Rating for Rezolute (RZLT) with $5 Target Pr - GuruFocus
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism - StreetInsider
Jefferies reiterates Buy rating on Rezolute stock, maintains $4 target - Investing.com
Rezolute Hopes To Find A Way Forward In Congenital HI After Phase III Miss - Citeline News & Insights
Rezolute (RZLT) Shows Promising Results in Hypoglycemia Treatmen - GuruFocus
Can Rezolute's SunRIZE Study, Tumor HI Data Redefine Treatment For Hyperinsulinism? - Nasdaq
Rezolute (RZLT) Analyzes Phase 3 sunRIZE Study Outcomes - GuruFocus
Rezolute shares mixed results from Phase 3 trial for rare disease therapy - Investing.com Nigeria
Rezolute shares mixed results from Phase 3 trial for rare disease therapy By Investing.com - Investing.com South Africa
Rezolute rises as drug shows promise for rare low blood sugar disorders - TradingView — Track All Markets
Rezolute, Inc. Shares Findings on Ersodetug's Efficacy for Congenital and Tumor Hyperinsulinism, Plans FDA Meeting to Discuss Path Forward - Quiver Quantitative
Rezolute, Inc. Provides Insights from sunRIZE Study and EAP - TradingView — Track All Markets
Potential Securities Fraud: Levi & Korsinsky Investigates Rezolute, Inc. (RZLT) - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. ... - Bluefield Daily Telegraph
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - Barchart.com
Rezolute Inc Stock (RZLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):